Data from Qualigen Therapeutics’ Lead Program QN-302 Accepted as Three Poster Presentations at AACR 2022 Conference

Rhea-AI Summary

Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announced the acceptance of three abstracts for poster presentations at the American Association of Cancer Research (AACR) conference, scheduled for April 8-13, 2022, in New Orleans. The abstracts focus on QN-302, a compound aimed at treating pancreatic cancer and other tumors. Presentations include insights on the compound's anti-tumor activity in various cancer models. Qualigen continues to advance its pipeline of oncology treatments, including QN-247 and other investigational compounds targeted at cancer proliferation.

Positive

• Three abstracts on QN-302 accepted for presentation at AACR conference.
• QN-302 shows promise as a treatment for pancreatic cancer and other tumors.

Negative

• None.

Posters to be Presented During the In-Person Conference Being Held April 8-13, 2022 in New Orleans

CARLSBAD, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announces that three abstracts on aspects of the Company’s recently in-licensed compound from University College -London, QN-302, have been accepted as posters to be presented at the prestigious American Association of Cancer Research (AACR) conference in April. QN-302 (previously known as SOP1812) is the Company’s genomic quadruplex (G4)-selective transcription inhibitor platform being developed as a potential treatment for pancreatic ductal adenocarcinoma (PDAC), in addition to other tumors of high unmet clinical need.
The three abstracts include:

Abstract Number:	2926
Title:	“Structure-based design of quadruplex-binding small molecule compounds: The essential role of water molecules”
Lead Author:	Dr. Stephen Neidle
Session Title:	Structural and Chemical Biology
Session Date and Time:	Tuesday Apr 12, 2022 9:00 AM - 12:30 PM CDT
Abstract Number:	4069
Title:	“The potent quadruplex-binding compound SOP1812 shows anti-tumor activity in patient-derived in vivo models of pancreatic cancer”
Lead Author:	Dr. Stephen Neidle
Session Title:	New Chemotherapy Agents
Session Date and Time:	Wednesday Apr 13, 2022 9:00 AM - 12:30 PM CDT
Abstract Number:	4068
Title:	“The potent quadruplex-binding compound SOP1812 shows potent anti-proliferative activity in a prostate cancer cell panel and anti-tumor activity in an in vivo model of metastatic prostate cancer”
Lead Author:	Dr. Stephen Neidle
Session Title:	New Chemotherapy Agents
Session Date and Time:	Wednesday Apr 13, 2022 9:00 AM - 12:30 PM CDT

The AACR Conference, being held in New Orleans from April 8-13, 2022, is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine.

About Qualigen Therapeutics, Inc.

Qualigen Therapeutics, Inc. is a biotechnology company focused on developing treatments for cancer, as well as maintaining and expanding its core FDA-cleared FastPack^® System, which has been used successfully in diagnostics for 20 years. Our investigational QN-302 compound is a small molecule selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells; such binding could, by stabilizing the G4s against “unwinding,” help inhibit cancer cell proliferation. Our investigational QN-247 compound inhibits nucleolin, a key multi-functional regulatory protein that is overexpressed in cancer cells; QN-247 may be able to inhibit the cells’ proliferation. QN-247 has shown promise in preclinical studies for the treatment of acute myeloid leukemia (AML). The investigational compounds within Qualigen’s RAS-F family of RAS oncogene protein-protein interaction inhibitor small molecules are believed to inhibit or block the binding of mutated RAS genes’ proteins to their effector proteins, thereby leaving the proteins from the mutated RAS unable to cause further harm. In theory, such mechanism of action may be effective in the treatment of about one quarter of all cancers, including certain forms of pancreatic, colorectal, and lung cancers. In addition to its oncology drug pipeline, Qualigen has an established diagnostics business which manufactures and distributes proprietary and highly accurate rapid blood testing systems to physician offices and small hospitals for the management of prostate cancer and other diseases and health conditions.

For more information about Qualigen Therapeutics, Inc., please visit www.qualigeninc.com.

Forward-Looking Statements

This news release contains forward-looking statements by Qualigen that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. These statements include those related to the Company's prospects and strategy for the development of therapeutic drug candidates. Actual events or results may differ from the Company's expectations. For example, there can be no assurance that the Company will successfully develop any drugs (including QN-302, QN-247 and RAS-F); that preclinical development of the Company's drugs (including QN-302, QN-247 and RAS-F, and its deprioritized infectious-disease drug candidate QN-165) will be completed on any projected timeline or will be successful; that any clinical trials will be approved to begin by or will proceed as contemplated by any projected timeline, or at all; that any future clinical trial data will be favorable or that such trials will confirm any improvements over other products or lack negative impacts; that any drugs will receive required regulatory approvals (or Fast Track designation or Orphan Drug status) or that they will be commercially successful; that patents will issue on the Company's owned and in-licensed patent applications; that such patents, if any, and the Company's currently owned and inlicensed patents would prevent competition; that the Company will be able to procure or earn sufficient working capital to complete the development, testing and launch of the Company's prospective therapeutic products (including QN-302, QN-247 and RAS-F, and QN-165); or that the Company will be able to maintain or expand market demand and/or market share for the Company's diagnostic products. The Company's stock price could be harmed if any of the events or trends contemplated by the forward-looking statements fails to occur or is delayed or if any actual future event otherwise differs from expectations. Additional information concerning these and other risk factors affecting the Company's business can be found in the Company's prior filings with the Securities and Exchange Commission, including its most recent Form 10-K, all of which are available at www.sec.gov.

The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this news release, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Investor Relations:

David Kugelman
Atlanta Capital Partners, LLC
(404) 856-9157 or (866) 692-6847 Toll Free - U.S. & Canada
dk@atlcp.com

Tony Schor
Investor Awareness, Inc.
(847) 971-0922
tony@investorawareness.com

Media:

Jules Abraham
JQA Partners, Inc.
917-885-7378
jabraham@jqapartners.com

Source: Qualigen Therapeutics, Inc.

FAQ

What is QN-302 and what is its significance for QLGN?

QN-302 is a compound developed by Qualigen Therapeutics, aimed at treating pancreatic cancer and other tumors, highlighting the company's focus on addressing high unmet clinical needs.

When will the AACR conference take place where QLGN will present?

The AACR conference will take place from April 8-13, 2022, in New Orleans.

What are the key findings related to QN-302 presented at the AACR conference?

The presentations will discuss QN-302's structure-based design and its anti-tumor activity in various cancer models, emphasizing its potential as a treatment.

How does QN-302 differ from other treatments for cancer?

QN-302 is a genomic quadruplex-selective transcription inhibitor, which may offer a unique mechanism of action compared to traditional cancer therapies.

What does the acceptance of these abstracts mean for QLGN?

The acceptance of the abstracts indicates recognition of QLGN's research efforts and could enhance investor interest and validation of its oncology pipeline.